Publications
NET RETREAT the CCTG NE1 trial has recently opened in North America looking to compare retreatment of Peptide Receptor Radionuclide Therapy versus standard treatment in patients with metastatic midgut neuroendocrine tumours.
Neoadjuvant Chemotherapy, Excision And Observation Vs Chemoradiotherapy For Early Rectal Cancer. The NEO-RT Trial
Paclitaxel and Ramucirumab +/- Zanidatamab in HER2 Positive Advanced Gastroesophageal Adenocarcinoma
OptimICE-pCR: De-escalation of Therapy in Early-Stage TNBC Patients who Achieve pCR after Neoadjuvant Chemotherapy with Checkpoint Inhibitor Therapy
Fixed Duration vs Continuous Daratumumab in Transplant Ineligible Older Adults with Newly Diagnosed Multiple Myeloma
A Phase III Randomized Study of Nivolumab (Opdivo) or Brentuximab Vedotin (Adcetris) plus AVD in Patients (age >/= 12 Years) with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma
MRD Driven Study of Venetoclax + Chemotherapy for Newly Diagnosed Younger Patients with Intermediate Risk AML
Master Screening and Reassessment Protocol (MSRP) for Tier Advancement in the NCI MYELOMATCH Clinical Trials
Novel Therapeutics in Younger Patients with High-Risk AML (MM1YA-S01)
Eradicating MRD in patients with AML prior to Stem Cell Transplant (ERASE)
MODERN: An Integrated Phase 2/3 and Phase 3 Trial of MRD-Based Optimization of ADjuvant ThErapy in URothelial CaNcer
Radiotherapy to Block (CURB2) Oligoprogression In Metastatic Non-Small-Cell Lung Cancer
On Wednesday September 19th 2018, CCTG's Director, Dr. Janet Dancey aired on the Blind Date with Knowledge radio show. During her interview Dr. Dancey talks about Evolving Clinical Trials through Collaboration. She discussed how the collaborative study of medical interventions in the treatment of cancer has expanded to also investigate how lifestyle, radiation, surgical, and smoke cessation interventions can affect the entire spectrum of cancer treatment.
Smoragiewicz M, Bogaerts J, Calvo E, Marabelle A, Perrone A, Seymour L, Shalabi A, Siu LL, Tabernero J, Giaccone G. Design and conduct of early clinical studies of immunotherapy agent combinations: Recommendations from the task force on Methodology for the Development of Innovative Cancer Therapies (ONLINE) Ann Oncol mdy398, 2018.
The results of the CCTG LY.16 trial of Rituxmab plus Lenalidomide in Advanced Untreated Follicular Lymphoma (RELEVANCE), recently published in New England Journal of Medicine, has the potential to offer a new treatment option to lymphoma patients, that does not require chemotherapy.
Find out more.
Randomized Phase II Study of Reolysin in Patients With Previously Treated Advanced or Metastatic, Non Small Cell Lung Cancer Receiving Standard Salvage Therapy.
IND.210 A Randomized Phase II Study of Reolysin in Combination with FOLFOX6 and Bevacizumab or FOLFOX6 and Bevacizumab Al one in Patients with Metastatic Colorectal Cancer
The CCTG Trialblazers will be participating in the Kingston Mudmoiselle on September 15th - running, swimming, and crawling through 5km of mud, dirt and grime in support of the the Canadian Cancer Society!
The money raised from this event helps fund leading-edge cancer research that is improving cancer treatments, preventing cancer and saving lives; provide reliable and up-to-date information on cancer, risk reduction and treatment; offer vital community-based support services for people living with cancer and their families; and advocate for healthy public policies.
The Canadian Institute of Health Research (CIHR) has announced a project grant award of $860,628 over six years for a research project lead by the Canadian Cancer Trials Group (CCTG). The HN.10 study will investigate the potential benefits of the de-escalation of treatment for patients with tonsil cancer.
Oropharyngeal squamous cell carcinoma (OPSCC) is one of the most common forms of head and neck cancer. Although this type cancer is often associated with other risk factors, OPSCC related to human papillomavirus (HPV) infection has seen a dramatic increase globally.
Read more >
The CRC.8 clinical trial is a Randomized Phase II Study of Nivolumab after Combined Modality Therapy (CMT) in High-Risk Anal Cancer, which has been centrally activated. This randomized phase II clinical trial studies how well nivolumab after combined modality therapy works in treating patients with high risk stage II-IIIB anal cancer. Monoclonal antibodies, such as nivolumab, may interfere with the ability of tumor cells to grow and spread.